Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
0 hedge funds and large institutions have $0 invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $2.99M → $0 (-$2.99M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.03M |
| 2 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
-$728K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$222K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EC
1
EcoR1 Capital
San Francisco,
California
| – | -$2.03M | -200,000 | Closed |
|
|
SIA
2
SkyView Investment Advisors
Shrewsbury,
New Jersey
| – | -$728K | -71,773 | Closed |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$222K | -21,923 | Closed |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | -$7K | -647 | Closed |
|
EUCR Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q2 2023, worth a combined $0 — down 100% from $2.99M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EUCR and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.03M sold.
- 0 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $0 of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q2 2023 was EcoR1 Capital, an estimated $2.03M sold.
Based on aggregated 13F filings for Q2 2023.